期刊
CANCER CONTROL
卷 30, 期 -, 页码 -出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/10732748221149543
关键词
pancreatic; cancer; metastatic; FOLFIRINOX; colony-stimulating; G-CSF
类别
This study examined the impact of primary prophylaxis (PP) with granulocyte colony-stimulating factor (G-CSF) on the frequency of neutropenia and survival outcomes in patients with metastatic pancreatic adenocarcinoma (MPA) treated with FOLFIRINOX. The results showed that although the frequency of grade 3/4 neutropenia decreased, the risk of febrile neutropenia (FN) was low in the FOLFIRINOX treatment group without G-CSF, and it was not justified for routine use. However, further studies are needed to assess the potential role of G-CSF in improving survival in MPA patients treated with FOLFIRINOX.
IntroductionThe role of primary prophylaxis (PP) with granulocyte colony-stimulating factor (G-CSF) for patients with metastatic pancreatic adenocarcinoma (MPA) treated with FOLFIRINOX is unknown. We aimed to compare the frequencies of grades 3 or 4 neutropenia (G3/4N) and febrile neutropenia (FN) and survival outcomes according to the use of PP.MethodsThis is a retrospective study. We included patients with pathologically confirmed MPA treated with FOLFIRINOX in first-line. Patients who received primary prophylaxis (PP group) were compared to patients who received secondary or no G-CSF (no-PP group). Overall survival (OS) and progression-free survival (PFS) were evaluated using the standard Cox proportional hazard model. To account for potential biases, we performed sensitivity analyses excluding patients who received secondary prophilaxis and treating G-CSF as a time-dependent covariate in extended Cox proportional hazard models.ResultsThe study population consisted of 123 patients. PP was used by 75 patients (61.0%). G3/4 N occurred more frequently among patients without PP (10.7 vs 41.7%; P < .001). There was no difference in the frequency of FN between groups (5.3 vs 8.3%; P = .710). In multivariate analysis, PP was associated with a trend toward improved OS (HR = .66; 95% confidence interval [95% CI] .41 - 1.07; P = .094). In the multivariate model excluding patients with secondary prophylaxis (HR = .54; 95% CI 0.32 - .91; P = .022) and in the time-dependent model (HR = .47; 95% CI 0.28 - .80; P = .005), PP was associated with statistically superior OS.ConclusionsDespite the reduction in the frequency of G3/4N, the risk of FN among patients treated with FOLFIRINOX without G-CSF is too low to justify its use in a routine basis. However, given the potential of G-CSF to improve survival in this setting, further studies are warranted to assess its role during treatment with FOLFIRINOX for patients with MPA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据